FTC Report Shows Sharp Increase in Flavored E-cigarette Sales Among Youth

Sep.01.2022
FTC Report Shows Sharp Increase in Flavored E-cigarette Sales Among Youth
US FTC's report shows sharp rise in flavored disposable and menthol e-cigarette pod sales in 2020, raising concerns about teenage addiction.

The Federal Trade Commission (FTC) in the United States recently released its second report on national sales and advertising of electronic cigarettes, which highlighted a significant increase in the sales of flavored disposable e-cigarettes and menthol e-cigarette pods in 2020. This growth coincides with the federal government's ban on flavored pods, which was aimed at reducing the appeal of e-cigarettes among young people. However, the report suggests that instead of decreasing, the use of e-cigarettes among teenagers may be shifting towards alternative products. Furthermore, the report found that the distribution of free and discounted e-cigarettes, a practice that has been linked to an increase in teenage vaping rates, has reached an all-time high.


The Director of the Consumer Protection Bureau at the Federal Trade Commission, Samuel Levine, stated, "This report indicates that teenagers still face risks when purchasing flavored or discounted electronic cigarettes." "The evidence shows that e-cigarette marketers have excelled in avoiding FDA regulation and creating addictive products for young people.


Since 1967, the Federal Trade Commission (FTC) has been reporting annual tobacco sales, and has been reporting on smokeless tobacco sales since 1987. Last year, the FTC expanded its research into the industry and released its first report on electronic cigarettes. Electronic cigarettes, or e-cigarettes, are battery-powered devices used to inhale aerosol, which typically contains nicotine, flavorings, and other chemicals. The two main types of e-cigarettes are pods and disposables. Pods are rechargeable and can be used multiple times, with users typically replacing the pre-filled pod when it runs out. Disposables are not rechargeable or refillable and are discarded once the battery or e-liquid runs out.


This year's e-cigarette report covers sales and advertising data from 2019 and 2020. During this time, the US Food and Drug Administration (FDA) issued a policy prohibiting the sale of flavored e-cigarette pods, with the exception of menthol. Overall, the report found that total e-cigarette sales increased from $304.2 million in 2015 to $2.046 billion in 2018, growing to $2.703 billion in 2019 but decreasing to $2.24 billion in 2020. The FTC report notes that the 2020 decline may not represent the market due to significant industry changes. Key findings in the report include:


Major shift in flavored disposable e-cigarettes: Publicly available data shows that sales of flavored disposable e-cigarettes (not constrained by the FDA's 2020 policy) have significantly increased, with "other" flavored disposable products accounting for 77.6% of all disposable e-cigarette sales in December 2020. However, FTC data does not show an increase in disposable sales. Nevertheless, FTC data may not be representative of the disposable e-cigarette market. Among the five companies that submitted data for 2019-20, only two continued to sell disposable e-cigarettes in 2020 and those that continued to sell offered a more limited product line. In order to improve the representativeness of their industry sales data for future FTC reports, the FTC recently issued orders to four additional e-cigarette companies.


Sales of menthol pods greatly increased: Similarly, the report found that sales of remaining non-FDA banned flavored pods, specifically menthol, showed a significant increase, accounting for 63.5% of all pod sales in 2020.


Discounts for e-cigarettes reach historic high: Data also shows that e-cigarette discount prices reached a record-breaking $182.3 million in 2019. Although slightly decreasing in 2020, these discounts still remain the largest category of advertising expenses for e-cigarettes.


Almost Free E-cigarette Samples Doubled: Data collected from 2019 to 2020 shows that within just two years, spending on free and heavily discounted e-cigarette samples and distribution has increased by over 100%, making it the second largest expenditure category. The reason for this increase in 2020 was due to the FDA's ban on tobacco product sampling in 2016 to limit youth exposure, which led some companies to offer e-cigarettes at $1 or even lower prices, apparently to circumvent the ban.


The FTC's report provides an important market snapshot of the impact of the FDA's efforts to restrict the harmful use of e-cigarettes among teenagers, as well as a roadmap of additional steps the FDA can take to combat youth addiction to nicotine. There is significant evidence that flavored e-cigarettes still appeal to young people, which increases the serious potential for more American youth to become addicted to nicotine and its harmful effects on the body. The report shows that partially banning certain types of e-cigarettes using certain types of flavors is unlikely to successfully reduce youth addiction to nicotine through the use of e-cigarettes.


The FTC is also concerned about sales tactics used by electronic cigarette companies, particularly discounts on prices. Studies have shown that consumers are highly responsive to changes in tobacco product prices, with younger smokers being more strongly influenced than older ones. This research has led American surgeons to conclude that discounts on prices lead to an increase in tobacco use among young people. The FTC believes that similar discounts on prices for electronic cigarettes are also worrying. Efforts by the FDA to restrict free samples of electronic cigarettes appear to have prompted manufacturers to circumvent the ban by offering record discounts and almost free products.


The committee approved the 2019-2020 electronic cigarette report and corresponding data tables from the Federal Trade Commission with a 5-0 vote.


Attached is the second report on the sales and advertising of e-cigarettes throughout the country.


Statement:


This article has been compiled from third-party information and is intended for sharing and learning within the industry.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the truth or accuracy of the article's contents. The article's translation is only intended for communication and research within the industry.


Due to limitations in translation ability, the translated article may not fully reflect the original wording. Please refer to the original text for accuracy.


Regarding any domestic, Hong Kong, Macau, Taiwan, or foreign issues or positions, 2FIRSTS maintains complete alignment with the Chinese government.


Translated: The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report|CrossBar's High-Puff Vapes Draw Attention on Pennsylvania's 163-Product Directory as Link Between Earlier 1.3mL PMTA Filings and New 13mL Products Remains Unclear
Special Report|CrossBar's High-Puff Vapes Draw Attention on Pennsylvania's 163-Product Directory as Link Between Earlier 1.3mL PMTA Filings and New 13mL Products Remains Unclear
Pennsylvania began enforcing its electronic nicotine delivery system directory restrictions on October 19, 2026. Among 163 product listings recorded before enforcement, four CrossBar 20K disposables stood out with 13mL capacity, advertised puff counts of up to 20,000 and a flattened design distinct from conventional pod systems and compact disposables. Historical records identify earlier 1.3mL CrossBar products associated with Romo LLC, while newer 13mL products appeared in several state directories beginning in 2025 under entities including Blue Nine LLC. PMTA compliance expert Mr. K identified amendments and application ownership transfers as possible regulatory mechanisms, although neither has been confirmed in this case. Separately, Reynolds' $7.5 million acquisition of 16 PACHA products and related assets illustrates the commercial value of products linked to historic PMTA submissions.
Special Report
Oct.22
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
Less than a week after JUUL2 received U.S. FDA marketing authorization on August 28, 2026, JUUL Labs was sued for patent infringement in federal court in Delaware. AJ Marketing LLC filed the complaint on September 3, alleging that both JUUL 1 and JUUL2 infringe U.S. Patent No. 8,851,068 B2. The patent covers aspects of programmable electronic vaporization devices, including controls over dose delivery, usage frequency and operating parameters. The plaintiff is seeking reasonable royalties and ongoing royalties tied to the remaining life of the patent. JUUL has not yet publicly responded to the case.
Sep.10
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
Athletes Back Skoka's $21.5 Million Nicotine Pouch Venture: Can Its Consumer Health Founder Make an FDA-Focused Strategy Pay Off?
Athletes Back Skoka's $21.5 Million Nicotine Pouch Venture: Can Its Consumer Health Founder Make an FDA-Focused Strategy Pay Off?
U.S. nicotine pouch startup Skoka Inc. has raised $21.5 million and committed $15 million to an FDA regulatory and scientific research program. Founder Dan Aziz previously built dietary supplement brand Premama, which was acquired by Dr. Reddy's Laboratories in 2023. Skoka is combining proprietary formulations, ingredient transparency and equity investment from professional athletes. The company submitted a bundled PMTA covering 55 products on October 1, 2026. Aziz said Skoka declined an opportunity to enter retail in 2025, prioritizing product research and regulatory submissions instead. It now targets a U.S. retail launch in 2027, subject to FDA requirements. Its products have not received marketing authorization.
Business
Nov.04